PRPO

Precipio, Inc.

Precipio Inc is a diagnostics company, which has built a platform designed to eradicate the problem of misdiagnosis by harnessing the expertise and technology developed within academic institutions and delivering diagnostic information to physicians.

Precipio, Inc. (PRPO) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (C). The rating has held at C+ for 12 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 56.7
EV / EBITDA -710.6
Rev Growth YoY 8.3%
Gross Margin 44.6%
Price Return 3M -7.4%
Price Return 12M 10.7%
Catalyst Signal 0.00
Market Cap $39.7M
TTM Revenue $27.8M
Price / Sales 1.4
ROE -8.0%

Historical Factor Score Progression

Held C+ for 12 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C (2.5) C (2.2) B (3.2) C+ (2.7) C+ (2.6) C+ (2.7)
2026-11-07 C+ (2.6) C+ (2.8) B- (2.9) C (2.5) C+ (2.7) C+ (2.7)
2026-10-31 C+ (2.6) C+ (2.8) B- (2.9) C (2.3) C+ (2.7) C+ (2.7)
2026-10-24 C+ (2.6) C+ (2.8) B- (2.9) C (2.4) C+ (2.6) C+ (2.7)
2026-10-17 C+ (2.6) C+ (2.8) B- (2.9) C+ (2.7) C+ (2.6) C+ (2.7)
Page 1 of 8
…